TEVA
Teva Pharmaceutical Industries Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -0.2% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 151 | +7 | 369.28M | $12.48B | +9 | −1 |
| Q1 2026 | 146 | +3 | 327.68M | $9.78B | +10 | −8 |
| Q4 2025 | 144 | -1 | 326.44M | $10.18B | +3 | −3 |
| Q3 2025 | 23 | 0 | 176.53M | $3.56B | +1 | −2 |
| Q2 2025 | 21 | 0 | 197.53M | $3.31B | n/a | n/a |
| Q1 2025 | 18 | -3 | 84.56M | $1.30B | n/a | −3 |
| Q4 2024 | 21 | -1 | 89.79M | $1.98B | n/a | −1 |
| Q3 2024 | 21 | +2 | 78.93M | $1.23B | +2 | n/a |
| Q2 2024 | 19 | n/a | 61.88M | $1.01B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 58.14M | n/a | $974.35M | 0.1% | n/c | 1 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passive) | 54.32M | n/a | $910.38M | 0.0% | n/c | 1 | SEC ↗ ×20 |
| 3 | State Street Global Advisors ✦ (passive) | 17.29M | -0.2% | $289.73M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Duquesne Family Office ✦ | 15.97M | +7.3% | $267.64M | 6.8% | ▲ Add | 4 | SEC ↗ |
| 5 | Glenview Capital ✦ | 15.82M | +7.1% | $265.21M | 7.5% | ▲ Add | 5 | SEC ↗ |
| 6 | Viking Global Investors ✦ | 11.68M | +15.4% | $195.78M | 0.6% | ▲ Add | 4 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 9.63M | +4.7% | $160.25M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Greenlight Capital (DME Capital) ✦ | 3.78M | +565.0% | $63.33M | 2.7% | ▲ Add | 5 | SEC ↗ ×2 |
| 9 | Renaissance Technologies ✦ | 3.16M | -40.5% | $52.91M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 2.21M | -22.4% | $37.09M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 11 | Norges Bank ✦ (passive) | 1.86M | -27.9% | $31.25M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | Millennium Management ✦ | 1.10M | -80.0% | $18.42M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | The Vanguard Group ✦ (passive) | 885.45K | n/a | $14.84M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | Adage Capital Partners ✦ | 534.00K | +10.3% | $8.95M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 461.12K | +13.7% | $7.73M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 16 | Two Sigma Investments ✦ | 319.89K | +133.8% | $5.36M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 121.82K | +50.1% | $2.04M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 18 | ARK Investment Management ✦ | 120.87K | +33.9% | $2.03M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 19 | GAMCO Investors ✦ | 89.20K | -4.3% | $1.49M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 26.03K | +8.7% | $436,245 | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 21 | Wellington Management ✦ | 17.53K | -87.3% | $293,870 | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 646 holders, 666.61M shares, $16.70B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.52K sh · $98,841
Director · 367.60K sh · $14.36M
Officer · 4.50K sh · $174,221
Officer · 314 sh · $12,153
Officer · 2.50K sh · $94,077
Director · 415 sh · $15,459
Officer · 6.95K sh · $261,224
Officer · 18.60K sh · $680,291
Director · 17 sh · $593
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology